<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36615143</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Soluble ITGaM and ITGb2 Integrin Subunits Are Involved in Long-Term Pulmonary Complications after COVID-19 Infection.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">342</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm12010342</ELocationID><Abstract><AbstractText>(1) Introduction: The role of soluble integrins in post-COVID-19 complications is unclear, especially in long-term pulmonary lesions. The purpose of this study was to investigate the association between soluble ITGa2, ITGaM and ITGb2 integrin subunits and long COVID-19 pulmonary complications. (2) Methodology: Post-COVID-19 patients were enrolled. According to the evidence of persistent interstitial lung lesions on CT, patients were divided into a long-term pulmonary complications group (P(+)) and a control group without long-term pulmonary complications (P(-)). We randomly selected 80 patients for further investigation (40 subjects for each group). Levels of ITGa2, ITGaM and ITGb2 integrin subunits were determined by ELISA assay. (3) Results: The serum concentration of sITGaM and sITGb2 were significantly higher in the P(+) group (sITGaM 18.63 ng/mL [IQR 14.17-28.83] vs. 14.75 ng/mL [IQR 10.91-20] <i>p</i> = 0.01 and sITGb2 10.55 ng/mL [IQR 6.53-15.83] vs. 6.34 ng/mL [IQR 4.98-9.68] <i>p</i> = 0.002). We observed a statistically significant correlation between sITGaM and sITGb2 elevation in the P(+) group (R = 0.42; <i>p</i> = 0.01). Patients from the P(+) group had a lower (1.82 +/-0.84 G/L) lymphocyte level than the P(-)group (2.28 +/-0.79 G/L), <i>p</i> = 0.03. Furthermore, we observed an inverse correlation in the P(-) group between blood lymphocyte count and sITGb2 integrin subunit levels (R = -0.49 <i>p</i> = 0.01). (4) Conclusions: Elevated concentrations of sITGaM and sITGb2 were associated with long-term pulmonary complications in post-COVID-19 patients. Both sITGaM and sITGb2 may be promising biomarkers for predicting pulmonary complications and could be a potential target for therapeutic intervention in post-COVID-19 patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Siekacz</LastName><ForeName>Kamil</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6419-8074</Identifier><AffiliationInfo><Affiliation>Department of Pneumology, Medical University of Lodz, 90-419 Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumor-Kisielewska</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pneumology, Medical University of Lodz, 90-419 Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mi&#x142;kowska-Dymanowska</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1287-9289</Identifier><AffiliationInfo><Affiliation>Department of Pneumology, Medical University of Lodz, 90-419 Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pietrusi&#x144;ska</LastName><ForeName>Ma&#x142;gorzata</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pneumology, Medical University of Lodz, 90-419 Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartczak</LastName><ForeName>Krystian</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-7971-0771</Identifier><AffiliationInfo><Affiliation>Department of Pneumology, Medical University of Lodz, 90-419 Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majewski</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7210-5552</Identifier><AffiliationInfo><Affiliation>Department of Pneumology, Medical University of Lodz, 90-419 Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sta&#x144;czyk</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, Medical University of Lodz, 90-419 Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piotrowski</LastName><ForeName>Wojciech J</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0003-4506-6006</Identifier><AffiliationInfo><Affiliation>Department of Pneumology, Medical University of Lodz, 90-419 Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bia&#x142;as</LastName><ForeName>Adam J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Pneumology, Medical University of Lodz, 90-419 Lodz, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pulmonary Rehabilitation, Regional Medical Center for Lung Diseases and Rehabilitation, 91-520 Lodz, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD11b</Keyword><Keyword MajorTopicYN="N">CD18</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">ITGaM</Keyword><Keyword MajorTopicYN="N">ITGb2</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">fibrosis</Keyword><Keyword MajorTopicYN="N">integrins</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword><Keyword MajorTopicYN="N">post-COVID-19</Keyword><Keyword MajorTopicYN="N">pulmonary complications</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>8</Day><Hour>1</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36615143</ArticleId><ArticleId IdType="pmc">PMC9821073</ArticleId><ArticleId IdType="doi">10.3390/jcm12010342</ArticleId><ArticleId IdType="pii">jcm12010342</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Teuwen L.A., Geldhof V., Pasut A., Carmeliet P. COVID-19: The vasculature unleashed. Nat. Rev. Immunol. 2020;20:389&#x2013;391. doi: 10.1038/s41577-020-0343-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0343-0</ArticleId><ArticleId IdType="pmc">PMC7240244</ArticleId><ArticleId IdType="pubmed">32439870</ArticleId></ArticleIdList></Reference><Reference><Citation>Bednarczyk M., Stege H., Grabbe S., Bros M. &#x3b2;2 Integrins&#x2014;Multi-Functional Leukocyte Receptors in Health and Disease. Int. J. Mol. Sci. 2020;21:1402. doi: 10.3390/ijms21041402.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21041402</ArticleId><ArticleId IdType="pmc">PMC7073085</ArticleId><ArticleId IdType="pubmed">32092981</ArticleId></ArticleIdList></Reference><Reference><Citation>Gahmberg C.G. Leukocyte adhesion: CD11/CD18 integrins and intercellular adhesion molecules. Curr. Opin. Cell Biol. 1997;9:643&#x2013;650. doi: 10.1016/S0955-0674(97)80117-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0955-0674(97)80117-2</ArticleId><ArticleId IdType="pubmed">9330867</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S.-M. The leucocyte &#x3b2;2 (CD18) integrins: The structure, functional regulation and signalling properties. Biosci. Rep. 2012;32:241&#x2013;269. doi: 10.1042/BSR20110101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20110101</ArticleId><ArticleId IdType="pubmed">22458844</ArticleId></ArticleIdList></Reference><Reference><Citation>Walling B.L., Kim M. LFA-1 in T cell migration and differentiation. Front. Immunol. 2018;9:952. doi: 10.3389/fimmu.2018.00952.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00952</ArticleId><ArticleId IdType="pmc">PMC5943560</ArticleId><ArticleId IdType="pubmed">29774029</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitroulis I., Alexaki V.I., Kourtzelis I., Ziogas A., Hajishengallis G., Chavakis T. Leukocyte integrins: Role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol. Ther. 2015;147:123&#x2013;135. doi: 10.1016/j.pharmthera.2014.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2014.11.008</ArticleId><ArticleId IdType="pmc">PMC4324083</ArticleId><ArticleId IdType="pubmed">25448040</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigrist C.J., Bridge A., Le Mercier P. A potential role for integrins in host cell entry by SARS-CoV-2. Antivir. Res. 2020;177:104759. doi: 10.1016/j.antiviral.2020.104759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104759</ArticleId><ArticleId IdType="pmc">PMC7114098</ArticleId><ArticleId IdType="pubmed">32130973</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Lu F., Chen Y., Plow E., Qin J. Integrin mediates cell entry of the SARS-CoV-2 virus independent of cellular receptor ACE2. J. Biol. Chem. 2022;298:101710. doi: 10.1016/j.jbc.2022.101710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2022.101710</ArticleId><ArticleId IdType="pmc">PMC8828381</ArticleId><ArticleId IdType="pubmed">35150743</ArticleId></ArticleIdList></Reference><Reference><Citation>Luan J., Lu Y., Gao S., Zhang L. A potential inhibitory role for integrin in the receptor targeting of SARS-CoV-2. J. Infect. 2020;81:318&#x2013;356. doi: 10.1016/j.jinf.2020.03.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.046</ArticleId><ArticleId IdType="pmc">PMC7151354</ArticleId><ArticleId IdType="pubmed">32283163</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons P., Rinaldi D.A., Bondu V., Kell A.M., Bradfute S., Lidke D.S., Buranda T. Integrin activation is an essential component of SARS-CoV-2 infection. Sci. Rep. 2021;1:20398. doi: 10.1038/s41598-021-99893-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-99893-7</ArticleId><ArticleId IdType="pmc">PMC8516859</ArticleId><ArticleId IdType="pubmed">34650161</ArticleId></ArticleIdList></Reference><Reference><Citation>Makowski L., Olson-Sidford W., Weisel J.W. Biological and Clinical Consequences of Integrin Binding via a Rogue RGD Motif in the SARS CoV-2 Spike Protein. Viruses. 2021;13:146. doi: 10.3390/v13020146.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13020146</ArticleId><ArticleId IdType="pmc">PMC7909284</ArticleId><ArticleId IdType="pubmed">33498225</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma N.K., Kelleher D. Not Just an Adhesion Molecule: LFA-1 Contact Tunes the T Lymphocyte Program. J. Immunol. 2017;199:1213&#x2013;1221. doi: 10.4049/jimmunol.1700495.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1700495</ArticleId><ArticleId IdType="pubmed">28784685</ArticleId></ArticleIdList></Reference><Reference><Citation>Dana N., Fathallah D.M., Arnaout M.A. Expression of a soluble and functional form of the human &#x3b2;2 integrin CD11b/CD18. Proc. Natl. Acad. Sci. USA. 1991;88:3106&#x2013;3110. doi: 10.1073/pnas.88.8.3106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.88.8.3106</ArticleId><ArticleId IdType="pmc">PMC51394</ArticleId><ArticleId IdType="pubmed">1673028</ArticleId></ArticleIdList></Reference><Reference><Citation>Zen K., Guo Y.-L., Li L.-M., Bian Z., Zhang C.-Y., Liu Y. Cleavage of the CD11b extracellular domain by the leukocyte serprocidins is critical for neutrophil detachment during chemotaxis. Blood. 2011;117:4885&#x2013;4894. doi: 10.1182/blood-2010-05-287722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-05-287722</ArticleId><ArticleId IdType="pmc">PMC3100697</ArticleId><ArticleId IdType="pubmed">21403131</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjelstrup L.C., Boesen T., Kragstrup T.W., J&#xf8;rgensen A., Klein N.J., Thiel S., Winding B.W., Vorup-Jensen T. Shedding of Large Functionally Active CD11/CD18 Integrin Complexes from Leukocyte Membranes during Synovial Inflammation Distinguishes Three Types of Arthritis through Differential Epitope Exposure. J. Immunol. 2010;185:4154&#x2013;4168. doi: 10.4049/jimmunol.1000952.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1000952</ArticleId><ArticleId IdType="pubmed">20826754</ArticleId></ArticleIdList></Reference><Reference><Citation>Kragstrup T.W., Jalilian B., Hvid M., Kj&#xe6;rgaard A., &#xd8;stg&#xe5;rd R., Schi&#xf8;ttz-Christensen B., Jurik A.G., Robinson W.H., Vorup-Jensen T., Deleuran B. Decreased plasma levels of soluble CD18 link leukocyte infiltration with disease activity in spondyloarthritis. Arthritis Res. Ther. 2014;16:R42. doi: 10.1186/ar4471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4471</ArticleId><ArticleId IdType="pmc">PMC3978678</ArticleId><ArticleId IdType="pubmed">24490631</ArticleId></ArticleIdList></Reference><Reference><Citation>Kragstrup T.W., Juul-Madsen K., Christiansen S.H., Zhang X., Krog J., Vorup-Jensen T., Kj&#xe6;rgaard A.G. Altered levels of soluble CD18 may associate immune mechanisms with outcome in sepsis. Clin. Exp. Immunol. 2017;190:258&#x2013;267. doi: 10.1111/cei.13016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13016</ArticleId><ArticleId IdType="pmc">PMC5629430</ArticleId><ArticleId IdType="pubmed">28714582</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xf8;y S., Sandahl T.D., Hansen A.L., Deleuran B., Vorup-Jensen T., Vilstrup H., Kragstup T.W. Decreased monocyte shedding of the migration inhibitor soluble CD18 in alcoholic hepatitis. Clin. Transl. Gastroenterol. 2018;9:e160. doi: 10.1038/s41424-018-0022-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41424-018-0022-7</ArticleId><ArticleId IdType="pmc">PMC6002386</ArticleId><ArticleId IdType="pubmed">29904132</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniou K.M., Vasarmidi E., Russell A.-M., Andrejak C., Crestani B., Delcroix M., Dinh-Xuan A.T., Poletti V., Sverzellati N., Vitacca M., et al. European Respiratory Society statement on long COVID follow-up. Eur. Respir. J. 2022;60:2102174. doi: 10.1183/13993003.02174-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02174-2021</ArticleId><ArticleId IdType="pmc">PMC9349784</ArticleId><ArticleId IdType="pubmed">35144991</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., Villapol S. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci. Rep. 2021;11:16144. doi: 10.1038/s41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai A.D., Lavelle M., Boursiquot B.C., Wan E.Y. Long-term complications of COVID-19. Am. J. Physiol. Physiol. 2022;322:C1&#x2013;C11. doi: 10.1152/ajpcell.00375.2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00375.2021</ArticleId><ArticleId IdType="pmc">PMC8721906</ArticleId><ArticleId IdType="pubmed">34817268</ArticleId></ArticleIdList></Reference><Reference><Citation>NHIS&#x2014;Adult Tobacco Use&#x2014;Glossary.  [(accessed on 28 June 2022)]; Available online:  https://www.cdc.gov/nchs/nhis/tobacco/tobacco_glossary.htm.</Citation></Reference><Reference><Citation>Graham B.L., Steenbruggen I., Miller M.R., Barjaktarevic I.Z., Cooper B.G., Hall G.L., Hallstrand T.S., Kaminsky D.A., McCarthy K., McCormack M.C., et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am. J. Respir. Crit. Care Med. 2019;200:e70&#x2013;e88. doi: 10.1164/rccm.201908-1590ST.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201908-1590ST</ArticleId><ArticleId IdType="pmc">PMC6794117</ArticleId><ArticleId IdType="pubmed">31613151</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaysen-Andersen M., Venkatakrishnan V., Loke I., Laurini C., Diestel S., Parker B.L., Packer N.H. Human Neutrophils Secrete Bioactive Paucimannosidic Proteins from Azurophilic Granules into Pathogen-Infected Sputum. J. Biol. Chem. 2015;290:8789&#x2013;8802. doi: 10.1074/jbc.M114.631622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.631622</ArticleId><ArticleId IdType="pmc">PMC4423670</ArticleId><ArticleId IdType="pubmed">25645918</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilione M.R., Agosto L.M., Kennett M.J., Harvill E.T. CD11b is required for the resolution of inflammation induced by Bordetella bronchiseptica respiratory infection. Cell. Microbiol. 2006;8:758&#x2013;768. doi: 10.1111/j.1462-5822.2005.00663.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1462-5822.2005.00663.x</ArticleId><ArticleId IdType="pubmed">16611225</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorup-Jensen T., Lianli C., Gjelstrup L.C., Jensen U.B., Jewett C.A., Xie C., Shimaoka M., Linhardt R.J., Springer T.A. Binding between the Integrin X2 (CD11c/CD18) and Heparin. J. Biol. Chem. 2007;282:30869&#x2013;30877. doi: 10.1074/jbc.M706114200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M706114200</ArticleId><ArticleId IdType="pmc">PMC4142650</ArticleId><ArticleId IdType="pubmed">17699512</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland H.I., Nahill S.R., Maciaszek J.W., Welsh R.M. CD11b (Mac-1): A marker for CD8+ cytotoxic T cell activation and memory in virus infection. J. Immunol. 1992;149:1326&#x2013;1333. doi: 10.4049/jimmunol.149.4.1326.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.149.4.1326</ArticleId><ArticleId IdType="pubmed">1500720</ArticleId></ArticleIdList></Reference><Reference><Citation>Faridi M.H., Khan S.Q., Zhao W., Lee H.W., Altintas M.M., Zhang K., Kumar V., Armstrong A.R., Carmona-Rivera C., Dorschner J.M., et al. CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus. J. Clin. Investig. 2017;127:1271&#x2013;1283. doi: 10.1172/JCI88442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI88442</ArticleId><ArticleId IdType="pmc">PMC5373862</ArticleId><ArticleId IdType="pubmed">28263189</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisco M., Chao J.D., Kim I., Mogford J.E., Mayadas T.N., Mustoe T.A. Delayed wound healing in Mac-1 deficient mice is associated with normal monocyte recruitment. Wound Repair Regen. 2007;15:566&#x2013;571. doi: 10.1111/j.1524-475X.2007.00264.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1524-475X.2007.00264.x</ArticleId><ArticleId IdType="pubmed">17650101</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirahashi J., Mekala D., Van Ziffle J., Xiao L., Saffaripour S., Wagner D.D., Shapiro S.D., Lowell C., Mayadas T.N. Mac-1 Signaling via Src-Family and Syk Kinases Results in Elastase-Dependent Thrombohemorrhagic Vasculopathy. Immunity. 2006;25:271&#x2013;283. doi: 10.1016/j.immuni.2006.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.05.014</ArticleId><ArticleId IdType="pubmed">16872848</ArticleId></ArticleIdList></Reference><Reference><Citation>Walzog B., Seifert R., Zakrzewicz A., Gaehtgens P., Ley K. Cross-linking of CD18 in human neutrophils induces an increase of intracellular free Ca2+, exocytosis of azurophilic granules, quantitative up-regulation of CD18, shedding of L-selectin, and actin polymerization. J. Leukoc. Biol. 1994;56:625&#x2013;635. doi: 10.1002/jlb.56.5.625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jlb.56.5.625</ArticleId><ArticleId IdType="pubmed">7525820</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini G., Porte J., Weinreb P.H., Violette S.M., Wallace W.A., McKeever T.M., Jenkins G. &#x3b1;v&#x3b2;6 integrin may be a potential prognostic biomarker in interstitial lung disease. Eur. Respir. J. 2015;46:486&#x2013;494. doi: 10.1183/09031936.00210414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00210414</ArticleId><ArticleId IdType="pubmed">25745053</ArticleId></ArticleIdList></Reference><Reference><Citation>Song K.-H., Cho S.-J., Song J.-Y. &#x3b1;v&#x3b2;1 integrin as a novel therapeutic target for tissue fibrosis. Ann. Transl. Med. 2016;4:411. doi: 10.21037/atm.2016.10.33.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2016.10.33</ArticleId><ArticleId IdType="pmc">PMC5107387</ArticleId><ArticleId IdType="pubmed">27867963</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheppard D. The role of integrins in pulmonary fibrosis. Eur. Respir. Rev. 2008;17:157&#x2013;162. doi: 10.1183/09059180.00010909.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09059180.00010909</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokosaki Y., Nishimichi N. New Therapeutic Targets for Hepatic Fibrosis in the Integrin Family, &#x3b1;8&#x3b2;1 and &#x3b1;11&#x3b2;1, Induced Specifically on Activated Stellate Cells. Int. J. Mol. Sci. 2021;22:12794. doi: 10.3390/ijms222312794.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222312794</ArticleId><ArticleId IdType="pmc">PMC8657911</ArticleId><ArticleId IdType="pubmed">34884600</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullard D.C., Hu X., Schoeb T.R., Axtell R.C., Raman C., Barnum S.R. Critical Requirement of CD11b (Mac-1) on T Cells and Accessory Cells for Development of Experimental Autoimmune Encephalomyelitis. J. Immunol. 2005;175:6327&#x2013;6333. doi: 10.4049/jimmunol.175.10.6327.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.175.10.6327</ArticleId><ArticleId IdType="pubmed">16272284</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>